Key takeaways
- Thymosin β4 is a 43-amino-acid protein found in many cell types and in blood, saliva, tears and wound fluid; inside cells it binds single units of actin.
- It has been studied in rodent skin-wound and heart-injury models; a 2003 mouse study linked its overproduction in melanoma cells to more lung metastases.
- Human trials used eye drops, a skin gel and intravenous forms, enrolling from 4 to 700 people, with mixed results. The two published intravenous phase 1 studies (2010 and 2021) measured adverse events and blood levels in healthy volunteers.
- None of these trials tested TB-500; FDA staff write that thymosin β4 and TB-500 “are not the same substance”.
- It is not FDA-approved. Australia lists it in Schedule 4 and Appendix D of the Poisons Standard, and WADA prohibits it at all times under class S2.3.
01Thymosin beta 4 at a glance
The short version, dated 18 November 2026.
| Question | Thymosin beta 4 |
|---|---|
| What it is | A 43-amino-acid protein (Tβ4), first isolated from calf thymus |
| Where it is found | Many cell types; also blood, plasma, saliva, tears and wound fluid |
| What it does in cells | Binds single units of actin one to one and keeps them from joining filaments (T4) |
| Animal research | Rodent skin-wound and heart-injury models; a 2003 mouse study linked its overproduction in melanoma cells to more lung metastases (T3, T4) |
| Human trials | Eye drops, a skin gel and intravenous forms, in trials that enrolled from 4 to 700 people, with mixed results (T1/T2) |
| TB-500 | A different molecule: in FDA and HHS documents, a synthetic seven-amino-acid fragment of Tβ4. None of the trials tested it |
| United States | Not FDA-approved; Drugs@FDA lists no product containing it (18 Nov 2026) |
| United Kingdom | No result for “thymosin” on the electronic medicines compendium (18 Nov 2026) |
| Australia | Schedule 4 (prescription only) and Appendix D, clause 5, of the Poisons Standard October 2026 |
| WADA | Prohibited at all times, class S2.3: “Thymosin-β4 and its derivatives e.g. TB-500” (2026 List; the 2027 List keeps the entry) |
02What is thymosin beta 4?
Thymosin β4 is a protein of 43 amino acids. FDA’s 2026 review describes it as highly conserved, originally isolated from calf thymus and first proposed to be a thymic hormone. Later work found it in many cell types and in blood, plasma, saliva, tears and wound fluid.
Its best-documented job is structural. In 1991, researchers at the University of Pennsylvania showed that a peptide bound to most of the unassembled actin in resting human platelets was identical to thymosin β4. It binds single actin units one to one and keeps them from joining into filaments, the scaffolding cells use to hold their shape and move. Because it is so widespread and abundant, the authors proposed that it helps regulate actin assembly in many cell types (T4).
Not the same as TB-500. In FDA and HHS documents, TB-500 is a synthetic seven-amino-acid fragment of thymosin β4, positions 17 to 23, with an acetyl group added. FDA staff write that the two “are not the same substance”. The fragment has its own guide, TB-500, and the two are compared on TB-500 vs thymosin beta-4.
03How has thymosin beta 4 been studied in cells and animals?
Mostly in rodents and cell cultures. These studies show what researchers measured in those models; they are not evidence of an effect in people.
Skin wounds in aged mice, 2003 (T3). In a study summarised by FDA staff, researchers made small skin wounds on 26-month-old mice, applied either the full protein or an unacetylated seven-amino-acid stretch of it, and examined the tissue at day 7.
Heart injury in mice, 2025 (T3, T4). A team led from Fuwai Hospital in Beijing gave a recombinant form of thymosin β4 to mice after a coronary artery was blocked and reopened, or blocked permanently. They measured heart function, scarring and the size of the damaged area, and studied heart-muscle cells stressed by low oxygen in culture.
Tumours in mice, 2003 (T3, T4). Researchers at the US National Institutes of Health engineered mouse melanoma cells to make more thymosin β4. In mice, these cells formed larger tumours and about four times as many lung nodules as control cells, and in culture they migrated more. The authors proposed that thymosin β4 “may stimulate tumor metastasis” through cell migration and new blood-vessel growth. The tumour cells made the extra thymosin β4 themselves; the study did not give the protein as a treatment. It is a mouse and cell finding, and it does not show what giving thymosin β4 does, in mice or in people, in either direction.
None of these studies tested TB-500. How we grade studies like these: evidence grades.
04Which human trials have tested thymosin beta 4?
Every trial below used the full protein, synthetic or recombinant. They are described by design; across the programmes, results have been mixed.
| Form and condition | Design | People | Registry, 18 Nov 2026 |
|---|---|---|---|
| Eye drops (RGN-259), dry eye | Phase 2, randomised, placebo-controlled; published 2015 | 72 | Completed; results posted |
| Eye drops, severe dry eye | Phase 2, randomised, vehicle-controlled; published 2015 | 9 | Completed; results posted |
| Eye drops, dry eye (ARISE-1, -2, -3) | Phase 2/3, then two phase 3; randomised, placebo-controlled | 317; 601; 700 | Completed; results posted for ARISE-2 and ARISE-3 |
| Eye drops, neurotrophic keratopathy (SEER-1, SEER-2) | Phase 3, randomised, placebo-controlled; SEER-1 published 2022 | 18; 70 | SEER-1 ended early (“Business decision”); SEER-2 completed July 2026, no results posted |
| Eye drops, corneal wounds in diabetes | Phase 2, randomised, placebo-controlled | 12 | Ended early (slow recruitment) |
| Skin gel (RGN-137), venous stasis ulcers; pressure ulcers | Phase 2, randomised, placebo-controlled; the venous-ulcer trial, run in Italy and Poland, was published in 2010 (73 people randomised) | 72; 72 | Completed; results posted |
| Skin gel, epidermolysis bullosa | Phase 2, randomised, placebo-controlled | 30; 4 | Both ended early |
| Intravenous, synthetic, healthy volunteers | Phase 1, randomised, placebo-controlled, single and repeated administration; published 2010 | 40 | No completed record found; a record with the same design, NCT00743769, is marked withdrawn, never started |
| Intravenous, recombinant (NL005), healthy volunteers | Phase 1 in two parts, randomised, double-blind, placebo-controlled, single and repeated administration; published 2021 | 54; 30 | Both parts completed |
| Recombinant, after a heart attack | Phase 2, randomised, placebo-controlled, given intravenously (registry); a double-blind trial in 96 people treated for an ST-elevation heart attack was published in 2025 (its abstract does not give the route) | 62; 90; 189 planned | Two completed, no results posted; one not yet recruiting |
What they measured. According to the registry, the dry-eye trials measured eye discomfort and corneal staining; the keratopathy trials, complete closure of a corneal surface defect by day 29; most skin-gel trials, safety and tolerability, and the smallest, how quickly wounds shrank; and the heart-attack trials, the size of the damaged area of heart muscle. The healthy-volunteer studies measured adverse events and blood levels, and the 2021 study also measured antibodies against the drug.
Who ran them. Most eye-drop and gel trials were sponsored by RegeneRx Biopharmaceuticals or ReGenTree, and the recombinant trials by Beijing Northland Biotech. Three authors of the 2021 paper and three of the 2025 paper were employees of that company; three authors of the 2022 keratopathy paper were employed by the developer or its parent company.
None of these trials gave TB-500, and none was about sport. A result with a 43-amino-acid protein on the eye or skin says nothing direct about a seven-amino-acid fragment.
05Is thymosin beta 4 an approved medicine? Status by country
United States. No. A search of Drugs@FDA through openFDA returned no product with thymosin as an active ingredient on 18 November 2026. FDA’s 2026 compounding review concerned the fragment TB-500, not the full protein: see TB-500.
United Kingdom. A search of the electronic medicines compendium (emc), a database of UK licensed-medicine information, returned no results for “thymosin” on 18 November 2026. More: are peptides legal in the UK?
Australia. The Poisons Standard October 2026, in force from 1 October 2026, lists “THYMOSIN BETA 4 (THYMOSIN β4)” in Schedule 4 (prescription only) and in Appendix D, clause 5, “poisons for which possession without authority is illegal”. TB-500 has a separate entry. A schedule entry is not an approval. More: are peptides legal in Australia?
Sport. WADA’s 2026 Prohibited List names “Thymosin-β4 and its derivatives e.g. TB-500” in class S2.3, growth factors and growth factor modulators, prohibited at all times. The 2027 List, in force from 1 January 2027, keeps the entry. See peptides and anti-doping.
06What we don’t know about thymosin beta 4
- Whether it changes the course of any condition in people. The trials so far are phase 1 to 3, mostly company-sponsored, with mixed results, and none has led to an FDA-approved product.
- Its safety with longer use. The two intravenous studies in healthy volunteers were small and short.
- Whether giving thymosin β4 affects tumour growth in people. The 2003 finding comes from mouse tumour cells engineered to make more of it, and none of the human trials above had tumours as a primary outcome.
- Whether any of this applies to TB-500. None of the trials tested the fragment, and FDA staff say the two are not the same substance.
- Which molecule a given vial holds. The protein is about six times the length of the fragment, so a mass result on that lot’s report tells them apart: mass spectrometry explained.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.